Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
15N2-tofacitinib is a stable isotope-labeled form of tofacitinib, in which two nitrogen atoms are replaced with the ^15N isotope. It is primarily used as an internal standard in bioanalytical assays (such as LC-MS/MS) for the quantification of tofacitinib in biological samples. Tofacitinib itself is a small molecule Janus kinase (JAK) inhibitor that modulates immune function by inhibiting JAK1 and JAK3, and to a lesser extent JAK2, thereby interfering with cytokine signaling involved in inflammatory and autoimmune diseases. The labeled version does not have therapeutic use but supports pharmacokinetic and drug metabolism studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 15N2-tofacitinib.